Poolbeg Pharma has received a decision to grant a European [...]

Poolbeg Pharma has presented two posters at the European Hematology [...]

Poolbeg Pharma has activated the first clinical site and begun [...]

CytoAgents will present new clinical safety data for CTO1681 at [...]

CytoAgents, a clinical-stage biotechnology company developing an oral small-molecule immune [...]

Poolbeg Pharma has appointed Accelerating Clinical Trials (ACT) to run [...]

Poolbeg Pharma has been granted Orphan Drug Designation (ODD) by [...]